Interpace Biosciences, Inc.
Interpace Biosciences, Inc.
Your view on IDXG
Overview
What the company does, where it operates, and who runs it.
About Interpace Biosciences, Inc.
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Thomas W. Burnell
- Headquarters
- Morris Corporate Center 1, Parsippany, NJ, US
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
- CEO
- Thomas W. Burnell
- Headquarters
- Morris Corporate Center 1, Parsippany, NJ, US
Interpace Biosciences, Inc. provides molecular diagnostic tests, bioinformatics, and pathology services for evaluating cancer risk in the United States.
The company offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion genomic test that helps physicians better assess risk of pancreaticobiliary cancers using its PathFinderTG platform; PanDNA, a molecular only version of PancraGEN that provides physicians a snapshot of a limited number of factors; and ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules.
It also provides ThyraMIR assesses thyroid nodules for risk of malignancy utilizing a proprietary microRNA gene-expression assay; and RespriDx, a genomic test that helps physicians to differentiate metastatic or recurrent lung cancer.
The company also provides pharmacogenomics testing, genotyping, biorepository, and other customized services to the pharmaceutical and biotech industries. It primarily serves physicians, hospitals, and clinics. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019.
Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Interpace Biosciences, Inc., and the rating behind it. IDXG last traded at $1.74, 0.2× trailing earnings — the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Interpace Biosciences, Inc.. Starting points for Interpace Biosciences, Inc.: P/E 0.2, EPS $4.41, beta 1.15 — an Medical - Diagnostics & Research name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Interpace Biosciences, Inc.. Interpace Biosciences, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Interpace Biosciences, Inc.. Trailing twelve-month EPS for Interpace Biosciences, Inc. stands at $4.41. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Interpace Biosciences, Inc.. Interpace Biosciences, Inc. has reported as a listed company since 1998. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Interpace Biosciences, Inc. valued side by side against its closest peers. Interpace Biosciences, Inc. is measured against Medical - Diagnostics & Research peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Interpace Biosciences, Inc., and how their positions are changing. At a $7.7M market value, institutional positions materially move Interpace Biosciences, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Interpace Biosciences, Inc. executives and directors. Shares of Interpace Biosciences, Inc. have traded between $0.44 and $1.91 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Interpace Biosciences, Inc.. Interpace Biosciences, Inc. is a $7.7M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Interpace Biosciences, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Interpace Biosciences, Inc.. Coverage tracks Interpace Biosciences, Inc. within Medical - Diagnostics & Research (Healthcare). Press releases and market coverage, newest first.